Cancer Gene Therapy · 2018 · 98 citations · 26 references
MedicineCancer BiologyOncologyCell TherapyImmunotherapyMolecular OncologyCancer ImmunotherapyCell-based TherapeuticsTargeted Cancer TherapyTargeted TherapyTumor AntigensTumor-associated AntigensCancer Targeting LigandsGlioblastoma ImmunotherapyGlioblastoma Targeted TherapyPro-apoptotic AgentsTrail ReceptorsTumor Targeting LigandsTumor-associated Antigen RecognitionTumor-associated Antigen Targeting
Tumor targeting by genetically modified mesenchymal stromal/stem cells (MSCs) carrying anti-cancer molecules represents a promising cell-based strategy. We previously showed that the pro-apoptotic agent tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be successfully delivered by MSCs to cancer sites. While the interaction between TRAIL and its receptors is clear, more obscure is the way in which MSCs can selectively target tumors and their antigens. Several neuroectoderm-derived neoplasms, including glioblastoma (GBM), sarcomas, and neuroblastoma, express high levels of the tumor-associated antigen GD2. We have already challenged this cell surface disialoganglioside by a chimeric antigen receptor (CAR)-T cell approach against neuroblastoma. With the intent to maximize the therapeutic profile of MSCs delivering TRAIL, we here originally developed a bi-functional strategy where TRAIL is delivered by MSCs that are also gene modified with the truncated form of the anti-GD2 CAR (GD2 tCAR) to mediate an immunoselective recognition of GD2-positive tumors. These bi-functional MSCs expressed high levels of TRAIL and GD2 tCAR associated with a robust anti-tumor activity against GD2-positive GBM cells. Most importantly, the anti-cancer action was reinforced by the enhanced targeting potential of such bi-functional cells. Collectively, our results suggest that a truncated anti-GD2 CAR might be a powerful new tool to redirect MSCs carrying TRAIL against GD2-expressing tumors. This affinity-based dual targeting holds the promise to combine site-specific and prolonged retention of MSCs in GD2-expressing tumors, thereby providing a more effective delivery of TRAIL for still incurable cancers.
26
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Akira Nakamizo, Frank C. Marini, Toshiyuki Amano et al. · Cancer Research · 2005 · 1K citations
Medicine, Cell Biology, Oncology +8
Glioblastoma multiforme: The terminator
Eric C. Holland · Proceedings of the National Academy of Sciences · 2000 · 771 citations
Medicine, Neuroscience, Oncology +10
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Kiminori Nakamura, Yoshinori Ito, Yutaka Kawano et al. · Gene Therapy · 2004 · 593 citations
Medicine, Cell Biology, Oncology +15